PMC:7696151 / 66728-66990 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1977","span":{"begin":115,"end":118},"obj":"Chemical"},{"id":"1978","span":{"begin":120,"end":134},"obj":"Chemical"},{"id":"1996","span":{"begin":227,"end":247},"obj":"Disease"}],"attributes":[{"id":"A1977","pred":"tao:has_database_id","subj":"1977","obj":"MESH:D006886"},{"id":"A1978","pred":"tao:has_database_id","subj":"1978","obj":"MESH:D012460"},{"id":"A1996","pred":"tao:has_database_id","subj":"1996","obj":"MESH:D001172"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"A multicenter, randomized clinical trial analyzed the tolerability and the efficacy of combined therapy, including HCQ, sulphasalazine, MXT, and PRD with respect to the use of a single antirheumatic drug in the caring of early rheumatoid arthritis for two years."}

{"project":"LitCovid-PD-HP","denotations":[{"id":"T125","span":{"begin":227,"end":247},"obj":"Phenotype"}],"attributes":[{"id":"A125","pred":"hp_id","subj":"T125","obj":"http://purl.obolibrary.org/obo/HP_0001370"}],"text":"A multicenter, randomized clinical trial analyzed the tolerability and the efficacy of combined therapy, including HCQ, sulphasalazine, MXT, and PRD with respect to the use of a single antirheumatic drug in the caring of early rheumatoid arthritis for two years."}

{"project":"LitCovid-sentences","denotations":[{"id":"T429","span":{"begin":0,"end":262},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"A multicenter, randomized clinical trial analyzed the tolerability and the efficacy of combined therapy, including HCQ, sulphasalazine, MXT, and PRD with respect to the use of a single antirheumatic drug in the caring of early rheumatoid arthritis for two years."}